Lamis Eldjerou

3.9k total citations
22 papers, 260 citations indexed

About

Lamis Eldjerou is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Lamis Eldjerou has authored 22 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Hematology and 4 papers in Molecular Biology. Recurrent topics in Lamis Eldjerou's work include CAR-T cell therapy research (10 papers), Virus-based gene therapy research (3 papers) and Biomedical Ethics and Regulation (3 papers). Lamis Eldjerou is often cited by papers focused on CAR-T cell therapy research (10 papers), Virus-based gene therapy research (3 papers) and Biomedical Ethics and Regulation (3 papers). Lamis Eldjerou collaborates with scholars based in United States, Switzerland and Spain. Lamis Eldjerou's co-authors include John R. Wingard, Yanni Hao, Helen Leather, Hidefumi Hiramatsu, William B. Slayton, Rowan J. Milner, Mai He, Ada Baisre, Geneviève Gauthier and Monrat Chulanetra and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Lamis Eldjerou

22 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lamis Eldjerou United States 10 178 65 55 45 38 22 260
Noa G. Holtzman United States 8 148 0.8× 96 1.5× 47 0.9× 32 0.7× 38 1.0× 51 273
Razan Mohty United States 10 149 0.8× 80 1.2× 47 0.9× 26 0.6× 23 0.6× 43 257
Forat Lutfi United States 10 194 1.1× 41 0.6× 54 1.0× 44 1.0× 37 1.0× 49 257
Ben Carpenter United Kingdom 11 160 0.9× 77 1.2× 128 2.3× 48 1.1× 18 0.5× 28 320
Uri Greenbaum Israel 9 117 0.7× 37 0.6× 55 1.0× 23 0.5× 36 0.9× 26 232
Ali Bukhari United States 9 206 1.2× 21 0.3× 27 0.5× 45 1.0× 40 1.1× 25 297
David M. Cordas dos Santos Germany 8 251 1.4× 49 0.8× 45 0.8× 34 0.8× 32 0.8× 16 304
Ana Cordeiro Brazil 5 332 1.9× 35 0.5× 47 0.9× 89 2.0× 68 1.8× 21 400
James I. Barnes United States 6 243 1.4× 25 0.4× 80 1.5× 37 0.8× 39 1.0× 10 353
Agrima Mian United States 8 151 0.8× 22 0.3× 20 0.4× 33 0.7× 32 0.8× 36 248

Countries citing papers authored by Lamis Eldjerou

Since Specialization
Citations

This map shows the geographic impact of Lamis Eldjerou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lamis Eldjerou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lamis Eldjerou more than expected).

Fields of papers citing papers by Lamis Eldjerou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lamis Eldjerou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lamis Eldjerou. The network helps show where Lamis Eldjerou may publish in the future.

Co-authorship network of co-authors of Lamis Eldjerou

This figure shows the co-authorship network connecting the top 25 collaborators of Lamis Eldjerou. A scholar is included among the top collaborators of Lamis Eldjerou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lamis Eldjerou. Lamis Eldjerou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bono, Johann S. de, Michael J. Morris, Oliver Sartor, et al.. (2024). Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.. Journal of Clinical Oncology. 42(16_suppl). 5008–5008. 7 indexed citations
2.
3.
Buechner, Jochen, Stephan A. Grupp, Hidefumi Hiramatsu, et al.. (2021). Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Advances. 5(2). 593–601. 39 indexed citations
4.
5.
Broder, Michael S., Qiufei Ma, Tingjian Yan, et al.. (2020). Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.. PubMed Central. 13(5). 192–199. 7 indexed citations
6.
Chulanetra, Monrat, Elias Sayour, Lamis Eldjerou, et al.. (2020). GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.. PubMed. 10(2). 674–687. 41 indexed citations
7.
Krueger, Joerg, Susana Rives, André Baruchel, et al.. (2020). Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).. Journal of Clinical Oncology. 38(15_suppl). 10518–10518. 9 indexed citations
8.
Hiramatsu, Hidefumi, Souichi Adachi, Katsutsugu Umeda, et al.. (2019). Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia. International Journal of Hematology. 111(2). 303–310. 11 indexed citations
9.
Ericson, Solveig G., Lamis Eldjerou, Eric Bleickardt, et al.. (2019). Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy. Current Hematologic Malignancy Reports. 14(1). 47–55. 11 indexed citations
10.
Eldjerou, Lamis, Christopher M. Acker, Florence Salmon, et al.. (2019). Tisagenlecleucel Manufacturing Feasibility in Patients Less Than 3 Years of Age with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood. 134(Supplement_1). 5066–5066. 5 indexed citations
11.
Broder, Michael S., Qiufei Ma, Tingjian Yan, et al.. (2019). Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States. Blood. 134(Supplement_1). 4719–4719. 2 indexed citations
12.
Chari, Ajai, Menaka Bhor, Lamis Eldjerou, et al.. (2018). Treatment Patterns and Medication Adherence Among Patients Diagnosed with Multiple Myeloma and Treated with Panobinostat. Future Oncology. 14(21). 2149–2160. 5 indexed citations
13.
Eldjerou, Lamis, Jie Zhang, & Christopher Hunt Keir. (2018). Disease Characteristics and Outcomes in Adult Patients with Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation. 24(3). S125–S125. 2 indexed citations
14.
15.
Maziarz, Richard T., Yanni Hao, Annie Guérin, et al.. (2017). Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. Leukemia & lymphoma. 59(5). 1133–1142. 25 indexed citations
16.
Chulanetra, Monrat, Elias Sayour, Lamis Eldjerou, et al.. (2015). Abstract 3157: Novel GD2-specific chimeric antigen receptor-modified T cells targeting osteosarcoma. Cancer Research. 75(15_Supplement). 3157–3157. 1 indexed citations
17.
Eldjerou, Lamis, et al.. (2014). Rare form of autosomal dominant thalassemia—Hemoglobin Hakkari. Pediatric Blood & Cancer. 61(11). 2118–2120. 2 indexed citations
18.
Sugrue, Michele W., Michael J. Haller, Susan S. Kelly, et al.. (2012). Characteristics of thawed autologous umbilical cord blood. Transfusion. 52(10). 2234–2242. 15 indexed citations
19.
Wingard, John R., Lamis Eldjerou, & Helen Leather. (2011). Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia. Current Opinion in Hematology. 19(1). 21–26. 18 indexed citations
20.
Eldjerou, Lamis, Sonali Chaudhury, Ada Baisre, et al.. (2010). An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment. Blood. 116(19). 3999–4006. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noa G. Holtzman Breakdown of academic impact, for papers by Razan Mohty Breakdown of academic impact, for papers by Forat Lutfi Breakdown of academic impact, for papers by Ben Carpenter Breakdown of academic impact, for papers by Uri Greenbaum Breakdown of academic impact, for papers by Ali Bukhari Breakdown of academic impact, for papers by David M. Cordas dos Santos Breakdown of academic impact, for papers by Ana Cordeiro Breakdown of academic impact, for papers by James I. Barnes Breakdown of academic impact, for papers by Agrima Mian
Rankless by CCL
2026